Risk factor
Meaningful price volatility
Profitability factor
Greatly overvalued vs peers
About
Guangzhou LBP Medicine Science & Technology Co., Ltd. specializes in the development and manufacture of innovative pathological diagnostic solutions for the Chinese market. Its comprehensive product portfolio includes advanced pathological diagnostic reagents and essential ancillary equipment. Among these are liquid-based cytology (LBC) offerings, encompassing both gynecological and non-gynecological series, complemented by specialized equipment. The company also provides fluorescence in situ hybridization (FISH) products, which are applied across a broad spectrum of conditions. These applications range from various cancers, including breast, bladder, lung, cervical, prostate, and thyroid, to other complex diagnoses such as neuroblastoma, soft tissue sarcoma, diverse solid tumors, prenatal screening, complications in abortion, oligodendrocytes tumors, lymphoma, multiple myeloma, and several forms of leukemia (chronic myelogenous, chronic lymphocytic, acute myeloid, and acute lymphoblastic), as well as myelodysplastic syndromes. Furthermore, GLBP offers immunohistochemistry (IHC) products, comprising a range of antibodies, advanced detection and repair systems, complementary products, and complete IHC kits. Additionally, its capabilities extend to molecular genetic diagnosis products. Established in 2005, Guangzhou LBP Medicine Science & Technology Co., Ltd. is headquartered in Guangzhou, China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB